Chromos Licenses Cellular Engineering Tech to Pfizer

Chromos Molecular Systems said last week that it will non-exclusively license to Pfizer its ACE System to develop cell lines for research, development, and manufacturing of Pfizer products.

The licensing agreement expands upon an original agreement announced in December, under which Chromos is using the ACE System to engineer cell lines to express a Pfizer protein. Pfizer will continue to support this work, Chromos said.

Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.